Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. announced that the Ministry of Health, Labour and Welfare in Japan has granted Orphan Drug designation for zeleciment basivarsen, for the treatment of myotonic muscular dystrophy type 1.